“…Clinical staging of cervical cancers is accurate in only approximately 60% of cases, which is far less than surgical staging accuracy [2,3]. Lymph node metastasis is not a factor for FIGO staging; however, nodal metastases in gynecologic malignancies have an adverse impact on survival, especially in cases of paraaortic node involvement in cervical cancer [4,5]. Although nodal resection before radiation therapy results in a higher survival rate in patients with grossly enlarged pelvic and paraaortic lymph nodes [6,7], routine pretreatment surgical staging is not recommended.…”
WEBThis is a Web exclusive article.OBJECTIVE. The purpose of this article is to assess the accuracy of MRI in detecting pelvic and paraaortic lymph node metastasis from uterine cervical cancer using various imaging criteria.CONCLUSION. Although MRI analysis resulted in relatively low sensitivity, size and margin (spiculated or lobulated) were useful criteria for predicting lymph node metastasis from cervical cancer.ervical cancer is the second most frequently diagnosed malignancy in women worldwide, and it is the only major gynecologic malignancy clinically staged according to International Federation of Obstetrics and Gynecology (FIGO) recommendations [1]. Clinical staging of cervical cancers is accurate in only approximately 60% of cases, which is far less than surgical staging accuracy [2,3]. Lymph node metastasis is not a factor for FIGO staging; however, nodal metastases in gynecologic malignancies have an adverse impact on survival, especially in cases of paraaortic node involvement in cervical cancer [4,5]. Although nodal resection before radiation therapy results in a higher survival rate in patients with grossly enlarged pelvic and paraaortic lymph nodes [6,7], routine pretreatment surgical staging is not recommended. For this reason, inaccurate pretreatment assessment of lymph node involvement can lead to suboptimal treatment [8,9].CT and MRI have been used to assess paraaortic and pelvic lymph nodes in patients with cervical cancer. A meta-analysis of such studies concluded that these methods have only moderate sensitivity and specificity for detecting metastases [10]. These studies relied on the size and shape of lymph nodes, and the analyses were based on region-specific comparisons. It was reported that margin and appearance are valid criteria for assessing lymph node metastasis from rectal cancer [11]. However, to our knowledge, no reports define the validity of criteria other than size and shape, and no reports have described node-by-node comparisons in the detection of metastatic pelvic lymph nodes in patients with uterine cervical carcinoma.The purpose of this study was to assess the accuracy of MRI in detecting metastatic lymph nodes in cervical cancer patients using various imaging criteria.
Materials and Methods
Patients and Staging WorkupPatients included in this retrospective study were those with histopathologically confirmed FIGO stages IB-IVA invasive cervical cancer, which was determined by a conventional workup that included MRI. Patients were recruited between October 2001 and October 2004, ranged in age from 18 to 65 years (mean age, 48 years), had no contraindications to the surgical procedure, had no evidence of distant metastases, and had an Eastern Cooperative Oncology Group performance status of 0-1. Patients with small cell carcinoma (n = 2) and patients who were not to undergo laparoscopic lymph node dissection (n = 63) were excluded.After histologic confirmation of invasive cervical carcinoma, the FIGO stage was determined using bimanual pelvic examination, excretory urograp...
“…Clinical staging of cervical cancers is accurate in only approximately 60% of cases, which is far less than surgical staging accuracy [2,3]. Lymph node metastasis is not a factor for FIGO staging; however, nodal metastases in gynecologic malignancies have an adverse impact on survival, especially in cases of paraaortic node involvement in cervical cancer [4,5]. Although nodal resection before radiation therapy results in a higher survival rate in patients with grossly enlarged pelvic and paraaortic lymph nodes [6,7], routine pretreatment surgical staging is not recommended.…”
WEBThis is a Web exclusive article.OBJECTIVE. The purpose of this article is to assess the accuracy of MRI in detecting pelvic and paraaortic lymph node metastasis from uterine cervical cancer using various imaging criteria.CONCLUSION. Although MRI analysis resulted in relatively low sensitivity, size and margin (spiculated or lobulated) were useful criteria for predicting lymph node metastasis from cervical cancer.ervical cancer is the second most frequently diagnosed malignancy in women worldwide, and it is the only major gynecologic malignancy clinically staged according to International Federation of Obstetrics and Gynecology (FIGO) recommendations [1]. Clinical staging of cervical cancers is accurate in only approximately 60% of cases, which is far less than surgical staging accuracy [2,3]. Lymph node metastasis is not a factor for FIGO staging; however, nodal metastases in gynecologic malignancies have an adverse impact on survival, especially in cases of paraaortic node involvement in cervical cancer [4,5]. Although nodal resection before radiation therapy results in a higher survival rate in patients with grossly enlarged pelvic and paraaortic lymph nodes [6,7], routine pretreatment surgical staging is not recommended. For this reason, inaccurate pretreatment assessment of lymph node involvement can lead to suboptimal treatment [8,9].CT and MRI have been used to assess paraaortic and pelvic lymph nodes in patients with cervical cancer. A meta-analysis of such studies concluded that these methods have only moderate sensitivity and specificity for detecting metastases [10]. These studies relied on the size and shape of lymph nodes, and the analyses were based on region-specific comparisons. It was reported that margin and appearance are valid criteria for assessing lymph node metastasis from rectal cancer [11]. However, to our knowledge, no reports define the validity of criteria other than size and shape, and no reports have described node-by-node comparisons in the detection of metastatic pelvic lymph nodes in patients with uterine cervical carcinoma.The purpose of this study was to assess the accuracy of MRI in detecting metastatic lymph nodes in cervical cancer patients using various imaging criteria.
Materials and Methods
Patients and Staging WorkupPatients included in this retrospective study were those with histopathologically confirmed FIGO stages IB-IVA invasive cervical cancer, which was determined by a conventional workup that included MRI. Patients were recruited between October 2001 and October 2004, ranged in age from 18 to 65 years (mean age, 48 years), had no contraindications to the surgical procedure, had no evidence of distant metastases, and had an Eastern Cooperative Oncology Group performance status of 0-1. Patients with small cell carcinoma (n = 2) and patients who were not to undergo laparoscopic lymph node dissection (n = 63) were excluded.After histologic confirmation of invasive cervical carcinoma, the FIGO stage was determined using bimanual pelvic examination, excretory urograp...
“…Kasper et al 11 confirmed the report by Burghardt and Holzer 9 and Burghardt 10 that a tumour volume exceeding 500 mm 3 is an adverse prognostic indicator for cervical adenocarcinoma. They found no recurrence among patients with a tumour volume of 500 mm 3 or less.…”
Section: Discussionmentioning
confidence: 67%
“…They found no recurrence among patients with a tumour volume of 500 mm 3 or less. However, the maximum tumour volume of FIGO stages IA1 and IA2 tumours (if not exophytic or multifocal lesions) is 220.5 (3 Â 7 Â 10.5) mm 3 and 367.5 (5 Â 7 Â 10.5) mm 3 , respectively. Thus, we assume that the borderline tumour volume to define microinvasive cervical adenocarcinoma should be set at nearly half of that in Kasper et al's report 11 .…”
Section: Discussionmentioning
confidence: 95%
“…The tumours with a horizontal spread of 7 mm or less were defined as stage IA1 if the invasive component had a depth of 3 mm or less and as stage IA2 if the invasive component was 3 -5 mm in depth 1 . Several investigators 2,3 agree with this definition because of its close correlation to the incidence of nodal disease or recurrence, while others 4,5 who consider that capillary space involvement is important disagree with this classification since the presence or absence of capillary involvement does not alter the stage. Although not universally accepted, the FIGO classification (1994) is increasingly used as the basis of treatment guidelines for squamous cell carcinoma.…”
“…The prognostic factors identified in cervical cancer patients are tumor size, depth of stromal invasion, presence of lymphovascular tumor emboli, histologic type, and invasion of surgical margins [2,3]. Lymph node metastasis is also closely associated with poor prognosis and decreased survival rate [4]; moreover, this metastasis is an indicator for adjuvant radiotherapy [5].…”
Lymph node metastasis is an important prognostic factor in cervical cancer patients. We report THz imaging for detecting micro-metastatic foci in the lymph nodes of early-stage uterine cervical cancer patients. Five paraffin-embedded metastatic lymph nodes from two cervical cancer patients were imaged using a THz time-domain spectroscopy system in the reflection mode. The size and shape of the tumor regions were compared with those from histopathologic examinations. The metastatic portions of lymph nodes as small as 3 mm were well delineated by THz imaging. The reflected peak amplitudes were lower in metastatic portions than in the normal portions of lymph nodes, and the difference in their peak-to-peak amplitudes was ~5%.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.